The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1–Infected Individuals
{"Image DocumentName": "The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1\u2013Infected Individuals", "Image ImageDescription": "In 1 year, about half of patients needed to start ART in Delayed Treatment group. Time to meeting eligibility criteria for initiation or reinitiation of antiretroviral therapy (ART) for the immediate treatment (IT) and deferred treatment (DT) groups over the 96 weeks of the study; times were significantly longer in the IT group (P < .001; log\u2013rank test). CD4 <350 criteria to initiate ARV. Time to meeting eligibility criteria for initiation or reinitiation of antiretroviral therapy (ART) for the immediate treatment (IT) and deferred treatment (DT) groups over the 96 weeks of the study; times were significantly longer in the IT group (P < .001; log\u2013rank test). Hogan C M et al. J Infect Dis. 2011;infdis.jir699.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}